Results 231 to 240 of about 1,504,154 (294)

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang   +4 more
wiley   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

open access: yesArthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah   +5 more
wiley   +1 more source

Gene Therapy of Beta Hemoglobinopathies. [PDF]

open access: yesBiomedicines
Testa U, Pelosi E, Castelli G.
europepmc   +1 more source

Lived and Care Experiences of Chronic Musculoskeletal Shoulder Pain in Australian Adults: A Qualitative Study

open access: yesArthritis Care &Research, EarlyView.
Objective Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person‐centered care and informing local service pathways and care guidelines or standards.
Sonia Ranelli   +8 more
wiley   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy